Replies to post #115946 on Biotech Values

[DewDiligence]

Why should [Teva] want a quick trial if it can launch at risk (with no risk)?

You’re overlooking one very important point: An at-risk cannot happen if the Judge imposes a preliminary injunction. Therefore, we may infer that Teva would surely want a speedy discovery process if it had any intention whatsoever of launching generic Lovenox in the next couple of years.

Enox-o-what? (#msg-59669784).